A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs WVE 120101 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; First in man
  • Acronyms PRECISION-HD1
  • Sponsors WaVe life Sciences
  • Most Recent Events

    • 08 Aug 2017 According to a WaVe life Sciences media release, completion of this trial is anticipated for 2H 2019.
    • 25 Jul 2017 New source identified and integrated (ClinicalTrials.gov; NCT03225833)
    • 17 Jul 2017 Status changed from planning to recruiting, according to a Wave Life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top